secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018795
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q1 loss $0.81; China roxadustat sales up 47%; pamrevlumab Ph3 data expected in 2023
--------------------------------------------------------------------------------

- Net loss $76.7M ($0.81/sh) vs $63.2M ($0.68/sh) in Q1 2022.
- Total revenue $36.2M, down from $60.8M (prior year included $25M milestone).
- China roxadustat net product revenue $24.2M (+28% YoY); total China sales $64.1M (+47%).
- Completed non-dilutive term loan facility of up to $150M with Morgan Stanley Tactical Value.
- Topline data from four Phase 3 trials (pamrevlumab in DMD, IPF, LAPC; roxadustat in CIA) expected through 3Q 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023018795/0000950170-23-018795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023018795/fgen-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer